These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 32507023)
1. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice. Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023 [TBL] [Abstract][Full Text] [Related]
2. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Rosenblatt RA; Andrilla CH; Catlin M; Larson EH Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888 [TBL] [Abstract][Full Text] [Related]
3. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. Andrilla CHA; Moore TE; Patterson DG; Larson EH J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Treatments for Opioid Use Disorder. Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832 [TBL] [Abstract][Full Text] [Related]
5. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653 [TBL] [Abstract][Full Text] [Related]
6. Medication Treatment of Opioid Use Disorder. Bell J; Strang J Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089 [TBL] [Abstract][Full Text] [Related]
7. Review of medication-assisted treatment for opioid use disorder. Ghanem N; Dromgoole D; Hussein A; Jermyn RT J Osteopath Med; 2022 Mar; 122(7):367-374. PubMed ID: 35285220 [TBL] [Abstract][Full Text] [Related]
8. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians. Andrilla CHA; Moore TE; Patterson DG J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720 [TBL] [Abstract][Full Text] [Related]
9. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors. Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136 [TBL] [Abstract][Full Text] [Related]
10. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440 [TBL] [Abstract][Full Text] [Related]
11. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. Ostrach B; Hill L; Carpenter D; Pollini R J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144 [TBL] [Abstract][Full Text] [Related]
12. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York. Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952 [TBL] [Abstract][Full Text] [Related]
13. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder. Andrilla CHA; Coulthard C; Larson EH Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273 [TBL] [Abstract][Full Text] [Related]
14. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine. Andrilla CHA; Jones KC; Patterson DG J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634 [TBL] [Abstract][Full Text] [Related]
15. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409 [TBL] [Abstract][Full Text] [Related]
16. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach. Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606 [TBL] [Abstract][Full Text] [Related]
17. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions. Gregory HM; Hill VM; Parker RW Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492 [TBL] [Abstract][Full Text] [Related]
18. The End of the X-waiver: Excitement, Apprehension, and Opportunity. LeFevre N; St Louis J; Worringer E; Younkin M; Stahl N; Sorcinelli M J Am Board Fam Med; 2023 Oct; 36(5):867-872. PubMed ID: 37704389 [TBL] [Abstract][Full Text] [Related]
19. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Ma J; Bao YP; Wang RJ; Su MF; Liu MX; Li JQ; Degenhardt L; Farrell M; Blow FC; Ilgen M; Shi J; Lu L Mol Psychiatry; 2019 Dec; 24(12):1868-1883. PubMed ID: 29934549 [TBL] [Abstract][Full Text] [Related]
20. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]